Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-05.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
High-Dose Intravenous Immune Globulin Therapy for Hyperbilirubinemia Caused by ABO Incompatibility

Journal of the Korean Pediatric Society 1993;36(8):1073-1079.
Published online August 15, 1993.
High-Dose Intravenous Immune Globulin Therapy for Hyperbilirubinemia Caused by ABO Incompatibility
Dong Sung Kim, Dong Un Kim, Ji Whan Han, Sung Soo Whang, Kyung Yil Lee, Man Kyu Yang
Department of Pediatrics, Catholic University Medical College, Seoul, Korea
ABO부적합 신생아 용혈성 질환에서의 대량 정맥용 면역글로불린 치료
김동성, 김동언, 한지환, 황성수, 이경일, 양만규
가톨릭대학교 의과대학 소아과학교실
Abstract
Four newborn infants with hyperbilirubinemia, caused by ABO blood group incompatibility, were treated with high-dose intravenous immune globulin (IVIG). As soon as the diagnosis was clinically suspected, these infants received conventional treatment including phototherapy and were monitored closely for bilirubin levels. When bilirubin concentrations reached the risk point in spite of pjototherapy, IVIG was given at a dose of 1g/kg for 6 hours. In all cases, bilirubin levels declined within 12 hours after IVEG therapy, and no rebound effect was seen. No side effects of IVIG treatment were observed. We suggest that high-dose IVIG therapy may be useful in the treatment of hyperbilirubinemia due to ABO incompatibility, and reduce the need for exchange transfusion.
Key Words: ABO incompatibility, Neonatal hyperbilirubinemia, Immune globulin therapy


METRICS Graph View
  • 1,910 View
  • 23 Download